AustralieFrV1, Main, Exploration, bibRecord, 004E57

Is It Cost-Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort

Identifieur interne : 004E57 ( Main/Exploration ); précédent : 004E56; suivant : 004E58

Is It Cost-Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort

Auteurs : Zanfina Ademi [Australie] ; Danny Liew [Australie] ; Bruce Hollingsworth [Australie] ; Ph. Gabriel Steg [France] ; Deepak L. Bhatt [États-Unis] ; Christopher M. Reid [Australie]

Source :

Cardiovascular therapeutics : (Print) [ 1755-5914 ] ; 2013.

RBID : Pascal:13-0086948

Descripteurs français

Pascal (Inist)
- Modélisation, Economie santé, Acide acétylsalicylique, Homme, Prévention, Australie, Santé publique, Cardiopathie coronaire, Analyse coût efficacité, Inhibiteur thromboagrégation, Antipyrétique, Analgésique, Antiinflammatoire non stéroïde.
Wicri :
- geographic : Australie.
- topic : Homme, Santé publique.

English descriptors

KwdEn :
- Acetylsalicylic acid, Analgesic, Antiplatelet agent, Antipyretic, Australia, Coronary heart disease, Cost efficiency analysis, Health economy, Human, Modeling, Non steroidal antiinflammatory agent, Prevention, Public health.

Abstract

Aims: To describe aspirin use in primary and secondary prevention and to determine the incremental costs-effectiveness ratio (ICER) per life year gain (LYG) of aspirin use among subjects with, or at high risk of atherothrombotic disease. Design and Subjects: To project the cost-effectiveness of aspirin over 5 years of follow-up, a Markov state transition model was developed with yearly cycles and the following health states: "Alive" (post-CAD) and "Dead." The model compared current coverage observed among 2361 subjects using the prospective Australian subset of Reduction of Atherothrombosis for continued Health (REACH) registry, and hypothetical situation whereby all subjects assumed to be treated. Costs were calculated based on the Australian government reimbursed data for 2010. Main outcome measures: ICER per LYG for increased use of aspirin. Results: The use of aspirin in current group varied from 67% to 70%. The base-case analysis showed that increasing aspirin use among subjects with existing CAD in outpatient settings was cost saving, while increasing use of aspirin in primary prevention equated to an ICER of AUD 7126 per LYG. Conclusion: Among subjects with existing CAD aspirin use was shown to be a dominant choice of treatment. However, among patients without existing cardiovascular disease (primary prevention), increased uptake of aspirin was cost effective but with uncertain benefit, with two hemorrhagic bleeding events occurring for every life saved.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000C15
to stream PascalFrancis, to step Curation: 005250
to stream PascalFrancis, to step Checkpoint: 000850
to stream Main, to step Merge: 005024
to stream Main, to step Curation: 004E57

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Is It Cost-Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort</title>
<author><name sortKey="Ademi, Zanfina" sort="Ademi, Zanfina" uniqKey="Ademi Z" first="Zanfina" last="Ademi">Zanfina Ademi</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Melbourne EpiCentre, Department of Medicine (The Royal Melbourne Hospital), The University of Melbourne</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Epidemiology & Preventive Medicine, Monash University</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Department of Epidemiology & Preventive Medicine, Monash University</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Liew, Danny" sort="Liew, Danny" uniqKey="Liew D" first="Danny" last="Liew">Danny Liew</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Melbourne EpiCentre, Department of Medicine (The Royal Melbourne Hospital), The University of Melbourne</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Hollingsworth, Bruce" sort="Hollingsworth, Bruce" uniqKey="Hollingsworth B" first="Bruce" last="Hollingsworth">Bruce Hollingsworth</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre for Health Economics, Monash University</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Centre for Health Economics, Monash University</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gabriel Steg, Ph" sort="Gabriel Steg, Ph" uniqKey="Gabriel Steg P" first="Ph." last="Gabriel Steg">Ph. Gabriel Steg</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>INSERM U-698, Universite Paris 7 and AP-HP</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bhatt, Deepak L" sort="Bhatt, Deepak L" uniqKey="Bhatt D" first="Deepak L." last="Bhatt">Deepak L. Bhatt</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>VA Boston Healthcare System, Brigham and Women's Hospital, Boston and Harvard Medical School</s1>
<s2>MA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Reid, Christopher M" sort="Reid, Christopher M" uniqKey="Reid C" first="Christopher M." last="Reid">Christopher M. Reid</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Epidemiology & Preventive Medicine, Monash University</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Department of Epidemiology & Preventive Medicine, Monash University</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0086948</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0086948 INIST</idno>
<idno type="RBID">Pascal:13-0086948</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C15</idno>
<idno type="wicri:Area/PascalFrancis/Curation">005250</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000850</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000850</idno>
<idno type="wicri:doubleKey">1755-5914:2013:Ademi Z:is:it:cost</idno>
<idno type="wicri:Area/Main/Merge">005024</idno>
<idno type="wicri:Area/Main/Curation">004E57</idno>
<idno type="wicri:Area/Main/Exploration">004E57</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Is It Cost-Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort</title>
<author><name sortKey="Ademi, Zanfina" sort="Ademi, Zanfina" uniqKey="Ademi Z" first="Zanfina" last="Ademi">Zanfina Ademi</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Melbourne EpiCentre, Department of Medicine (The Royal Melbourne Hospital), The University of Melbourne</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Epidemiology & Preventive Medicine, Monash University</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Department of Epidemiology & Preventive Medicine, Monash University</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Liew, Danny" sort="Liew, Danny" uniqKey="Liew D" first="Danny" last="Liew">Danny Liew</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Melbourne EpiCentre, Department of Medicine (The Royal Melbourne Hospital), The University of Melbourne</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Hollingsworth, Bruce" sort="Hollingsworth, Bruce" uniqKey="Hollingsworth B" first="Bruce" last="Hollingsworth">Bruce Hollingsworth</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre for Health Economics, Monash University</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Centre for Health Economics, Monash University</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gabriel Steg, Ph" sort="Gabriel Steg, Ph" uniqKey="Gabriel Steg P" first="Ph." last="Gabriel Steg">Ph. Gabriel Steg</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>INSERM U-698, Universite Paris 7 and AP-HP</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bhatt, Deepak L" sort="Bhatt, Deepak L" uniqKey="Bhatt D" first="Deepak L." last="Bhatt">Deepak L. Bhatt</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>VA Boston Healthcare System, Brigham and Women's Hospital, Boston and Harvard Medical School</s1>
<s2>MA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Reid, Christopher M" sort="Reid, Christopher M" uniqKey="Reid C" first="Christopher M." last="Reid">Christopher M. Reid</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Epidemiology & Preventive Medicine, Monash University</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Department of Epidemiology & Preventive Medicine, Monash University</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Cardiovascular therapeutics : (Print)</title>
<title level="j" type="abbreviated">Cardiovasc. ther. : (Print)</title>
<idno type="ISSN">1755-5914</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Cardiovascular therapeutics : (Print)</title>
<title level="j" type="abbreviated">Cardiovasc. ther. : (Print)</title>
<idno type="ISSN">1755-5914</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetylsalicylic acid</term>
<term>Analgesic</term>
<term>Antiplatelet agent</term>
<term>Antipyretic</term>
<term>Australia</term>
<term>Coronary heart disease</term>
<term>Cost efficiency analysis</term>
<term>Health economy</term>
<term>Human</term>
<term>Modeling</term>
<term>Non steroidal antiinflammatory agent</term>
<term>Prevention</term>
<term>Public health</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Modélisation</term>
<term>Economie santé</term>
<term>Acide acétylsalicylique</term>
<term>Homme</term>
<term>Prévention</term>
<term>Australie</term>
<term>Santé publique</term>
<term>Cardiopathie coronaire</term>
<term>Analyse coût efficacité</term>
<term>Inhibiteur thromboagrégation</term>
<term>Antipyrétique</term>
<term>Analgésique</term>
<term>Antiinflammatoire non stéroïde</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Australie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Santé publique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Aims: To describe aspirin use in primary and secondary prevention and to determine the incremental costs-effectiveness ratio (ICER) per life year gain (LYG) of aspirin use among subjects with, or at high risk of atherothrombotic disease. Design and Subjects: To project the cost-effectiveness of aspirin over 5 years of follow-up, a Markov state transition model was developed with yearly cycles and the following health states: "Alive" (post-CAD) and "Dead." The model compared current coverage observed among 2361 subjects using the prospective Australian subset of Reduction of Atherothrombosis for continued Health (REACH) registry, and hypothetical situation whereby all subjects assumed to be treated. Costs were calculated based on the Australian government reimbursed data for 2010. Main outcome measures: ICER per LYG for increased use of aspirin. Results: The use of aspirin in current group varied from 67% to 70%. The base-case analysis showed that increasing aspirin use among subjects with existing CAD in outpatient settings was cost saving, while increasing use of aspirin in primary prevention equated to an ICER of AUD 7126 per LYG. Conclusion: Among subjects with existing CAD aspirin use was shown to be a dominant choice of treatment. However, among patients without existing cardiovascular disease (primary prevention), increased uptake of aspirin was cost effective but with uncertain benefit, with two hemorrhagic bleeding events occurring for every life saved.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>France</li>
<li>États-Unis</li>
</country>
<region><li>Victoria (État)</li>
<li>Île-de-France</li>
</region>
<settlement><li>Melbourne</li>
<li>Paris</li>
</settlement>
<orgName><li>Université de Melbourne</li>
</orgName>
</list>
<tree><country name="Australie"><region name="Victoria (État)"><name sortKey="Ademi, Zanfina" sort="Ademi, Zanfina" uniqKey="Ademi Z" first="Zanfina" last="Ademi">Zanfina Ademi</name>
</region>
<name sortKey="Ademi, Zanfina" sort="Ademi, Zanfina" uniqKey="Ademi Z" first="Zanfina" last="Ademi">Zanfina Ademi</name>
<name sortKey="Hollingsworth, Bruce" sort="Hollingsworth, Bruce" uniqKey="Hollingsworth B" first="Bruce" last="Hollingsworth">Bruce Hollingsworth</name>
<name sortKey="Liew, Danny" sort="Liew, Danny" uniqKey="Liew D" first="Danny" last="Liew">Danny Liew</name>
<name sortKey="Reid, Christopher M" sort="Reid, Christopher M" uniqKey="Reid C" first="Christopher M." last="Reid">Christopher M. Reid</name>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Gabriel Steg, Ph" sort="Gabriel Steg, Ph" uniqKey="Gabriel Steg P" first="Ph." last="Gabriel Steg">Ph. Gabriel Steg</name>
</region>
</country>
<country name="États-Unis"><noRegion><name sortKey="Bhatt, Deepak L" sort="Bhatt, Deepak L" uniqKey="Bhatt D" first="Deepak L." last="Bhatt">Deepak L. Bhatt</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004E57 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004E57 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:13-0086948
   |texte=   Is It Cost-Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Is It Cost-Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort

Is It Cost-Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri